| human | Q5 |
| P496 | ORCID iD | 0000-0002-3403-9144 |
| P735 | given name | Jennifer | Q4677161 |
| Jennifer | Q4677161 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q33418091 | A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL |
| Q36888218 | Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia |
| Q90780075 | BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL |
| Q38729031 | BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia |
| Q34879367 | Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712 |
| Q33987045 | Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease |
| Q35903984 | Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia |
| Q40705355 | Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients |
| Q64120393 | Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL |
| Q37226729 | Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes |
| Q42909982 | Ibrutinib treatment improves T cell number and function in CLL patients |
| Q35812073 | Jumping translocations, a novel finding in chronic lymphocytic leukaemia |
| Q35958056 | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia |
| Q57169180 | Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia |
| Q37655012 | Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy |
| Q112576537 | Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia |
| Q27853011 | Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib |
| Q35953518 | Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study |
| Q90359786 | Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre |
| Q47300370 | Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial |
| Q90156412 | Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib |
Search more.